Karim Fizazi

Summary

Affiliation: Institut Gustave Roussy
Country: France

Publications

  1. ncbi request reprint The emerging role of antifolates in the treatment of malignant pleural mesothelioma
    Karim Fizazi
    Institut Gustave Roussy, Villejuif, France
    Semin Oncol 29:77-81. 2002
  2. ncbi request reprint [Clinical practice guidelines: Standards, Options and Recommendations for the diagnosis of carcinomas of unknown primary site]
    Thierry Lesimple
    Oncologue médical, Centre Eugene Marquis, Rennes
    Bull Cancer 90:1071-96. 2003
  3. ncbi request reprint Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma
    L Zelek
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Cancer 92:2267-72. 2001
  4. ncbi request reprint Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial
    Karim Fizazi
    Institut Gustave Roussy, University of Paris Sud, Villejuif, France Electronic address
    Lancet Oncol 15:975-85. 2014
  5. pmc The risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area
    A C Piketty
    Institut Gustave Roussy, Villejuif, France
    Br J Cancer 93:909-14. 2005
  6. doi request reprint A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective study
    Karim Fizazi
    Department of Cancer Medicine, Institut Gustave Roussy, Villejuif, France Electronic address
    Eur Urol 65:381-6. 2014
  7. doi request reprint Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer
    Karim S Fizazi
    Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, 39 rue Camille Desmoulins, Villejuif, France
    J Clin Oncol 31:1740-7. 2013
  8. doi request reprint Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial
    Karim Fizazi
    Institut Gustave Roussy and University of Paris XI, 39 rue Camille Desmoulins, Villejuif, France
    J Urol 189:S51-7; discussion S57-8. 2013
  9. doi request reprint A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial
    Karim Fizazi
    Institut Gustave Roussy, Villejuif, France
    Eur J Cancer 48:209-17. 2012
  10. ncbi request reprint High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer
    Karim Fizazi
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Anticancer Res 24:2897-903. 2004

Collaborators

Detail Information

Publications102 found, 100 shown here

  1. ncbi request reprint The emerging role of antifolates in the treatment of malignant pleural mesothelioma
    Karim Fizazi
    Institut Gustave Roussy, Villejuif, France
    Semin Oncol 29:77-81. 2002
    ..In both trials, survival is the main endpoint. These trials will help to define the role of these new antifolates in malignant pleural mesothelioma...
  2. ncbi request reprint [Clinical practice guidelines: Standards, Options and Recommendations for the diagnosis of carcinomas of unknown primary site]
    Thierry Lesimple
    Oncologue médical, Centre Eugene Marquis, Rennes
    Bull Cancer 90:1071-96. 2003
    ..The main objective is the development of clinical practice guidelines to improve the quality of health care and the outcome of cancer patients...
  3. ncbi request reprint Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma
    L Zelek
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Cancer 92:2267-72. 2001
    ..The objective of the study was to assess the tolerance and efficiency of weekly vinorelbine in metastatic breast carcinoma after failure with taxanes...
  4. ncbi request reprint Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial
    Karim Fizazi
    Institut Gustave Roussy, University of Paris Sud, Villejuif, France Electronic address
    Lancet Oncol 15:975-85. 2014
    ..This trial assessed ODM-201's safety, pharmacokinetics, and activity in men with metastatic castration-resistant prostate cancer...
  5. pmc The risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area
    A C Piketty
    Institut Gustave Roussy, Villejuif, France
    Br J Cancer 93:909-14. 2005
    ..This risk can be accurately predicted by serum LDH and body surface area. This predictive index may help to study prospectively the impact of thromboprophylaxis in GCT patients...
  6. doi request reprint A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective study
    Karim Fizazi
    Department of Cancer Medicine, Institut Gustave Roussy, Villejuif, France Electronic address
    Eur Urol 65:381-6. 2014
    ..Whether patients with good prognosis and intermediate/poor prognosis advanced seminoma should be treated differently has not been defined...
  7. doi request reprint Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer
    Karim S Fizazi
    Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, 39 rue Camille Desmoulins, Villejuif, France
    J Clin Oncol 31:1740-7. 2013
    ..7%), diarrhea (35.4%), alopecia (33.9%), and nausea (33.3%). CONCLUSION Docetaxel plus zibotentan 10 mg/d did not result in a significant improvement in OS compared with docetaxel plus placebo in patients with metastatic CRPC...
  8. doi request reprint Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial
    Karim Fizazi
    Institut Gustave Roussy and University of Paris XI, 39 rue Camille Desmoulins, Villejuif, France
    J Urol 189:S51-7; discussion S57-8. 2013
    ..Osteoclast mediated bone resorption can be assessed by measuring urine N-telopeptide and can be inhibited by denosumab, a fully human antibody against RANKL...
  9. doi request reprint A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial
    Karim Fizazi
    Institut Gustave Roussy, Villejuif, France
    Eur J Cancer 48:209-17. 2012
    ..To assess docetaxel-estramustine in patients with localised high-risk prostate cancer...
  10. ncbi request reprint High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer
    Karim Fizazi
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Anticancer Res 24:2897-903. 2004
    ..To assess the activity of docetaxel in combination with hormonal therapy in preclinical models of prostate cancer...
  11. ncbi request reprint Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors
    Karim Fizazi
    Genito Urinary Group of the French Federation of Cancer Centers, Paris, France
    J Clin Oncol 22:3868-76. 2004
    ....
  12. doi request reprint Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates
    Karim Fizazi
    Department of Medicine, Institut Gustave Roussy, University of Paris XI, Villejuif, France
    J Clin Oncol 27:1564-71. 2009
    ..We evaluated the effect of denosumab, a fully human monoclonal antibody against RANKL, in patients with bone metastases and elevated uNTx levels despite ongoing intravenous (IV) bisphosphonate (BP) therapy...
  13. ncbi request reprint High detection rate of circulating tumor cells in blood of patients with prostate cancer using telomerase activity
    K Fizazi
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 18:518-21. 2007
    ..Telomerase activation, one of the major immortalization events, is found in most cases of prostate cancer. We attempted to develop a method using telomerase activity to isolate CTCs in patients with prostate cancer...
  14. ncbi request reprint [Preclinical models of prostate cancer]
    Karim Fizazi
    Institut Gustave Roussy, Departement de Medecine, 39, rue Camille Desmoulins, 94800 Villejuif, France
    Bull Cancer 92:129-41. 2005
    ..This model allows to study the paracrine cross-talk between the two cell compartments and the resulting molecular modifications. The objective of the present article is to review the currently available model systems of prostate cancer...
  15. ncbi request reprint The role of Src in prostate cancer
    K Fizazi
    Department of Medicine, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94800 Villejuif, France
    Ann Oncol 18:1765-73. 2007
    ..Src inhibitors may be specifically evaluated in prostate cancer clinical trials in the near future...
  16. ncbi request reprint Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data
    Karim Fizazi
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Lancet Oncol 8:994-1000. 2007
    ..We aimed to assess whether combining estramustine with chemotherapy increases survival in patients with castration-refractory prostate cancer...
  17. ncbi request reprint Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study
    K Fizazi
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 19:259-64. 2008
    ..The purpose of this study was to validate a prognostic index [surgical complete response 1 (sCR1)] in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT)...
  18. doi request reprint Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer
    Karim Fizazi
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 27:2429-35. 2009
    ..To assess docetaxel combined with samarium-153-ethylene diamine tetramethylene phosphonic acid (EDTMP), a radiopharmaceutical with a high affinity for bone, in patients with castration-resistant prostate cancer (CRPC)...
  19. doi request reprint Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial
    Karim Fizazi
    Institut Gustave Roussy and University of Paris XI, Villejuif, France
    J Urol 182:509-15; discussion 515-6. 2009
    ..Osteoclast mediated bone resorption can be assessed by measuring urine N-telopeptide and can be inhibited by denosumab, a fully human antibody against RANKL...
  20. pmc Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
    Karim Fizazi
    Institut Gustave Roussy, University of Paris Sud, Villejuif, France
    Lancet 377:813-22. 2011
    ..We compared denosumab, a human monoclonal antibody against RANKL, with zoledronic acid for prevention of skeletal-related events in men with bone metastases from castration-resistant prostate cancer...
  21. doi request reprint Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer
    K Fizazi
    Institut Gustave Roussy, University of Paris Sud, Villejuif, France
    Eur J Cancer 48:85-93. 2012
    ....
  22. ncbi request reprint Germ cell tumors in patients infected by the human immunodeficiency virus
    K Fizazi
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Cancer 92:1460-7. 2001
    ..The objective of this study was to assess the natural history of the two disease courses, patient immune system tolerance, and results of therapy in human immunodeficiency virus (HIV)-infected patients with germ cell tumors (GCT)...
  23. ncbi request reprint Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study
    K Fizazi
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 21:349-54. 2003
    ..Most patients (66%) had advanced disease. Patients received raltitrexed 3 mg/m2 followed by oxaliplatin 130 mg/m2 every 3 weeks...
  24. pmc Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours
    K Fizazi
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Br J Cancer 86:1555-60. 2002
    ..Because outcomes with this regimen compare favourably with outcome after standard therapy, dose-dense chemotherapy should be further investigated in this subset of patients...
  25. ncbi request reprint Combination raltitrexed (Tomudex(R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma
    K Fizazi
    Department of Medicine, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94800, Villejuif, France
    Eur J Cancer 36:1514-21. 2000
    ..The efficacy/toxicity ratio of this combination compares favourably with that of our previous chemotherapy and chemo-immunotherapy regimens...
  26. ncbi request reprint Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer
    K Fizazi
    Institut Gustave Roussy, Villejuif, and AstraZeneca Pharmaceuticals, Cergy, France
    J Clin Oncol 18:2293-300. 2000
    ....
  27. ncbi request reprint A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: final results of a phase III randomized trial
    K Fizazi
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, USA
    Ann Oncol 13:125-34. 2002
    ....
  28. ncbi request reprint A phase II study of irinotecan in patients with advanced renal cell carcinoma
    Karim Fizazi
    Département de Médecine Institut Gustave Roussy, Villejuif, France
    Cancer 98:61-5. 2003
    ..Therefore, the authors tested the antitumor activity of irinotecan in patients with RCC...
  29. ncbi request reprint Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group
    K Fizazi
    Institut Gustave Roussy, Villejuif, Centre Leon Berard, Lyon, and Centre Val d Aurelle, Montpellier, France
    J Clin Oncol 19:2647-57. 2001
    ..To assess the value of postsurgery chemotherapy in patients with disseminated nonseminomatous germ-cell tumors (NSGCTs) and viable residual disease after first-line cisplatin-based chemotherapy...
  30. ncbi request reprint Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients
    K Fizazi
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 16:3736-43. 1998
    ..To assess the outcome and the prognosis of adults with a neoplasm related to the Ewing's sarcoma family of tumors...
  31. ncbi request reprint Is òne cycle every three or four weeks' obsolete? A critical review of dose-dense chemotherapy in solid neoplasms
    K Fizazi
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 11:133-49. 2000
    ..Our objective was to assess the clinical relevance of the rapid repetition of regimens (so-called 'dose-dense chemotherapy') in various solid neoplasms...
  32. doi request reprint Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors:
    Stephane Culine
    Centre Regional de Lutte contre le Cancer Val d Aurelle, Montpellier, France
    J Clin Oncol 26:421-7. 2008
    ..Two chemotherapy regimens for intermediate- and poor-risk metastatic nonseminomatous germ cell tumors were compared for efficacy and toxicity...
  33. doi request reprint Nonseminomatous germ cell tumors: assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis
    Benjamin Besse
    Institut Gustave Roussy, Villejuif, France
    J Thorac Cardiovasc Surg 137:448-52. 2009
    ..Our objective was to explore the pathologic components of residual masses after primary chemotherapy in patients with metastatic nonseminomatous germ cell tumors...
  34. ncbi request reprint [Management of localized germ-cell tumours of the testis]
    Yohann Loriot
    Departement de Medecine, Institut Gustave Roussy, Villejuif Cedex
    Rev Prat 57:379-84. 2007
    ..In non-seminomatous germ cell tumours three options should also be considered: surveillance (watchful waiting), chemotherapy by two cycles of BEP, or retroperitoneal lymph node dissection...
  35. ncbi request reprint Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer
    Antoine Italiano
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Eur Urol 55:1368-75. 2009
    ..There are no data on the patterns of care and outcome of very elderly patients with castration-resistant prostate cancer (CRPC) treated with docetaxel...
  36. ncbi request reprint The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer
    Yohann Loriot
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Eur J Cancer 46:1770-2. 2010
    ..The interval from the last cycle of first-line docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel...
  37. ncbi request reprint Gemcitabine and cisplatin after radical cystectomy for bladder cancer in an adjuvant setting: feasibility study from the Genito-Urinary Group of the French Federation of Cancer Centers
    Aude Flechon
    Department of Medical Oncology, Centre Leon Berard, Lyon, France
    Anticancer Drugs 17:705-8. 2006
    ..Whether this approach may increase survival is currently assessed in a randomized trial...
  38. pmc Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time
    Matthew R Smith
    Matthew R Smith, Massachusetts General Hospital Cancer Center, Boston, MA Fred Saad, University of Montreal Hospital Center, Montreal, Quebec, Canada Stephane Oudard, Georges Pompidou Hospital, Paris Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France Neal Shore, Carolina Urological Research Center, Myrtle Beach, SC Paul Sieber, Urological Associates of Lancaster, Lancaster, PA Bertrand Tombal, Université Catholique de Louvain Cliniques Universitaires Saint Luc, Bruxelles, Belgium Ronaldo Damiao, Hospital Universitario Pedro Ernesto, Rio de Janeiro, Brazil Gavin Marx, Sydney Haematology and Oncology Clinic, University of Sydney, Wahroonga, New South Wales, Australia Kurt Miller, Charite Berlin, Berlin, Germany Peter Van Veldhuizen, Kansas City Veterans Affairs Medical Center, Kansas City, MO Juan Morote, Hospital Vall d Hebron, Barcelona, Saudi Arabia
    J Clin Oncol 31:3800-6. 2013
    ..To identify men at greatest risk for bone metastasis or death, we evaluated relationships between PSA and PSADT with BMFS in the placebo group and the efficacy and safety of denosumab in men with PSADT ≤ 10, ≤ 6, and ≤ 4 months...
  39. doi request reprint Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients
    Antonin Levy
    Department of Medical Oncology, Gustave Roussy Institute, Paris XI University, Villejuif, France
    Eur J Cancer 49:1898-904. 2013
    ..However, very little is known on how many patients (pts) can receive second line or further, and on how to predict those pts. The goal of this study was to evaluate these questions in a large series of pts treated in our institution...
  40. doi request reprint Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
    Karim Fizazi
    Institut Gustave Roussy, University of Paris Sud, Villejuif, France
    Lancet Oncol 13:983-92. 2012
    ..Here, we present the final analysis of the study before crossover from placebo to abiraterone acetate (after 775 of the prespecified 797 death events)...
  41. doi request reprint Accelerated MVAC chemotherapy in patients with advanced bladder cancer previously treated with a platinum-gemcitabine regimen
    Julien Edeline
    Institut Gustave Roussy, Department of Cancer Medicine, University of Paris Sud, 39 rue Camille Desmoulins, Villejuif, France
    Eur J Cancer 48:1141-6. 2012
    ..There is no standard of care after failure of gemcitabine-platinum (GP) chemotherapy. Our aim was to assess the activity and toxicity of accelerated MVAC as second-line treatment...
  42. doi request reprint Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies
    Sami Antoun
    Department of Ambulatory Care, Institut Gustave Roussy, Villejuif, France
    Cancer 119:3377-84. 2013
    ..The objective of the current study was to analyze whether body composition parameters play a prognostic role in patients with mRCC...
  43. doi request reprint A risk-adapted strategy of radiotherapy or cisplatin-based chemotherapy in stage II seminoma
    Julien Domont
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Urol Oncol 31:697-705. 2013
    ..Indications for radiotherapy and chemotherapy in stage II seminoma are currently debated...
  44. ncbi request reprint [Locally advanced prostate cancer: definition, prognosis and treatment]
    Anne Plantade
    Departement de Medecine, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex
    Bull Cancer 94:F50-61. 2007
    ..In case of lymph node involvement, androgen deprivation is the standard treatment with an overall survival benefit. The place of local radiation therapy is still debating...
  45. ncbi request reprint Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01)
    Stephane Culine
    Department of Medical Oncology, Centre Regional de Lutte Contre le Cancer, Val d Aurelle, Parc Euromedecine, 34298 Montpellier Cedex 5, France
    J Clin Oncol 21:3479-82. 2003
    ..To evaluate the efficacy and toxicity of novel chemotherapy combinations including cisplatin with gemcitabine (GC) or irinotecan (IC) for patients with carcinomas of an unknown primary site...
  46. ncbi request reprint Long-term results of brachytherapy for carcinoma of the penis confined to the glans (N- or NX)
    Renaud de Crevoisier
    Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France
    Int J Radiat Oncol Biol Phys 74:1150-6. 2009
    ..To analyze the results of exclusive interstitial low-dose-rate brachytherapy (BT) for squamous cell carcinoma (SCC) of the penis, strictly confined to the glans...
  47. pmc Biological characterization of two xenografts derived from human CUPs (carcinomas of unknown primary)
    Delphine Lequin
    Universite Paris Sud, CNRS UMR 8126 and Institut Gustave Roussy, 39 rue Camille Desmoulins, F 94805 Villejuif, France
    BMC Cancer 7:225. 2007
    ..Although they often adopt an aggressive clinical pattern, their basic biology remains poorly understood. Laboratory research on their biology have been hampered so far by the absence of cell lines representative of CUPs...
  48. ncbi request reprint Compliance with guidelines and correlation with outcome in patients with advanced germ-cell tumours
    Constance Thibault
    Department of Cancer Medicine, University of Paris Sud, Institut Gustave Roussy, Villejuif, France
    Eur J Cancer 50:1284-90. 2014
    ..To evaluate prior compliance with guidelines in patients treated with salvage chemotherapy for advanced germ-cell tumours (GCT)...
  49. ncbi request reprint The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancer
    Karim Fizazi
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 8:775-81. 2002
    ..Another explanation involves the regulation of p21 expression by the androgen receptor, which also suggests that p21 may have antiapoptotic function in prostate cancer...
  50. pmc The IGR-CaP1 xenograft model recapitulates mixed osteolytic/blastic bone lesions observed in metastatic prostate cancer
    Nader Al Nakouzi
    Prostate Cancer Group, INSERM U981, Institut Gustave Roussy, Villejuif, France
    Neoplasia 14:376-87. 2012
    ....
  51. ncbi request reprint Advanced seminoma--treatment results and prognostic factors for survival after first-line, cisplatin-based chemotherapy and for patients with recurrent disease: a single-institution experience in 145 patients
    Dany Gholam
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Cancer 98:745-52. 2003
    ....
  52. ncbi request reprint Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer
    Antoine Angelergues
    Department of Medical Oncology, Georges Pompidou European Hospital, Paris, France
    Eur J Cancer 50:1602-9. 2014
    ..This flare has no standard definition. Its impact on treatment efficacy is unclear. We sought to evaluate the incidence and characteristics of PSA flare on cabazitaxel, and its impact on survival...
  53. doi request reprint [Treatment of testicular cancer]
    Jean Pierre Droz
    Universite Claude Bernard Lyon I, Centre Leon Berard, Departement d Oncologie Medicale, 28, rue Laennec, 69008 Lyon, France
    Bull Cancer 100:1319-32. 2013
    ..During the last three decades, clinical trials and strong international collaborations lead to the development of a consensus in the management of GCTs. ..
  54. ncbi request reprint Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts
    Karim Fizazi
    Departments of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 9:2587-97. 2003
    ....
  55. doi request reprint Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised tri
    Christopher J Logothetis
    University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Lancet Oncol 13:1210-7. 2012
    ....
  56. ncbi request reprint [Management of clinical stage I testicular germ cell tumours]
    Yohann Loriot
    Institut Gustave Roussy, 39 rue Camille Desmoulins, 94800 Villejuif
    Bull Cancer 94:439-48. 2007
    ..The strategy should be chosen taking into account predictive factors of relapse and the patient willing. Whatever the strategy, the cure rate is about 99%...
  57. doi request reprint The postchemotherapy PSA surge syndrome
    R Thuret
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 19:1308-11. 2008
    ..The objective of this work was to study early serum PSA changes in patients under chemotherapy and to correlate these changes with subsequent response assessment...
  58. ncbi request reprint Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of
    J P Lotz
    Department of Medical Oncology, Hopital Tenon, Paris, France
    Ann Oncol 16:411-8. 2005
    ..High-dose chemotherapy (HD-CT) is able to circumvent platinum resistance of resistant/refractory germ-cell tumors (GCTs), but expectancy of cure remains low. New strategies are needed with new drugs and a sequential approach...
  59. ncbi request reprint Stage I non-seminomatous germ-cell tumours of the testis: identification of a subgroup of patients with a very low risk of relapse
    J Alexandre
    Department of Medicine, Institut Gustave Roussy, 94805, Villejuif Cedex, France
    Eur J Cancer 37:576-82. 2001
    ..Patients who belong to this subgroup should be managed by surveillance only, instead of retroperitoneal lymph node dissection (RPLND) or adjuvant chemotherapy...
  60. ncbi request reprint Chemotherapy in patients with teratoma with malignant transformation
    Omar El Mesbahi
    Department of Medicine, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94800 Villejuif, France
    Eur Urol 51:1306-11; discussion 1311-2. 2007
    ..The only published series of patients with TMT treated with chemotherapy comprised 10 patients. We report here our experience in treating 14 patients with TMT...
  61. ncbi request reprint Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation--results of a prospective study
    M Saghatchian
    Institut Gustave Roussy, Villejuif, France
    Ann Oncol 12:535-40. 2001
    ..To evaluate the efficacy and toxicity of a chemotherapy strategy based on histological differentiation, for patients with carcinoma of unknown primary site...
  62. ncbi request reprint Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP)
    S Culine
    CRLC Val d Aurelle, Montpellier, France
    Ann Oncol 18:917-24. 2007
    ..High cure rates are expected in good-risk metastatic nonseminomatous germ-cell tumor (NSGCT) patients with bleomycin, etoposide and cisplatin...
  63. ncbi request reprint Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site
    Stephane Culine
    Centre Regional de Lutte contre le Cancer Val d Aurelle, Montpellier, France
    J Clin Oncol 20:4679-83. 2002
    ..To identify clinical and biologic variables with significant impact on survival in patients with carcinomas of an unknown primary site and to develop a simple prognostic model for the selection of patients in prospective clinical trials...
  64. ncbi request reprint Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data
    Charles Ferte
    Department of Medical Oncology, Gustave Roussy, Villejuif, France INSERM U981, Paris Sud University, Gustave Roussy, Villejuif, France Sage Bionetworks, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Eur Urol 65:713-20. 2014
    ..The tumor growth rate (TGR) incorporates the time between evaluations and may be adequate...
  65. doi request reprint Bone targeted therapies in metastatic castration-resistant prostate cancer
    Shanna Rajpar
    Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, 94800 Villejuif Cedex, France
    Cancer J 19:66-70. 2013
    ..Biomarkers of bone turnover have an independent prognostic impact...
  66. ncbi request reprint Role of targeted therapy in the treatment of advanced prostate cancer
    Karim Fizazi
    Institut Gustave Roussy, University of Paris XI, Villejuif, France
    BJU Int 105:748-67. 2010
    ....
  67. doi request reprint Sequential therapy in renal cell carcinoma
    Bernard Escudier
    Medical Oncology Department, Institut Gustave Roussy, Villejuif, France
    Cancer 115:2321-6. 2009
    ..Expecting a survival of 40 months does appear possible based on currently available data, although this assumption will have to be proven in the future...
  68. doi request reprint [Prognosis and predictive factors in prostate cancer]
    L Albiges-Sauvin
    Institut Gustave Roussy, 39 bis, rue Camille Desmoulins, 94800 Villejuif, France
    Bull Cancer 96:439-49. 2009
    ....
  69. doi request reprint Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer
    S Rajpar
    Department of Medicine, Institut Gustave Roussy, University of Paris XI, Villejuif, France
    Ann Oncol 21:1864-9. 2010
    ..The aim of this study was to assess the prognostic value of uNTx for overall survival (OS) and the incidence of SRE in patients with bone metastases from CRPC receiving zoledronic acid...
  70. doi request reprint Incidence of brain metastases in renal cell carcinoma treated with sorafenib
    C Massard
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 21:1027-31. 2010
    ..i.d.), versus placebo in the phase III Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGET)...
  71. doi request reprint Targeting continued androgen receptor signaling in prostate cancer
    Christophe Massard
    Institut Gustave Roussy, Department of Cancer Medicine, University of Paris Sud, Unité Inserm U981, Paris, France
    Clin Cancer Res 17:3876-83. 2011
    ....
  72. ncbi request reprint [Screening and early diagnosis of other cancers (non-small cell lung carcinoma, urologic cancers, liver cancer and melanoma)]
    Michel Ducreux
    Departement de Medecine, Institut Gustave Roussy, 94805 Villejuif
    Rev Prat 60:219-23. 2010
    ..Some cancers did not follow this rule because, for instance, the screening and early diagnosis of lung cancer among smokers is still a failure even when using the scanner...
  73. doi request reprint [High dose chemotherapy and germ cell tumor]
    Christophe Massard
    Institut Gustave Roussy, Departement de Medecine Oncologique, Villejuif, France
    Bull Cancer 98:945-9. 2011
    ..A randomized phase III trial has recently been initiated and patients with relapsed disease should be offered to participate in the trial. Several selected indications could be discussed in further lines of treatment...
  74. ncbi request reprint Primary mediastinal nonseminomatous germ cell tumors: results of modern therapy including cisplatin-based chemotherapy
    K Fizazi
    Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 16:725-32. 1998
    ..We describe the clinical and biologic features of these patients and evaluate the results of treatment during the cisplatin era...
  75. ncbi request reprint [New drugs in metastatic castration-resistant prostate cancer]
    L Albiges
    Institut Gustave Roussy, Departement de Medecine, 39 rue Camille Desmoulins, 94800 Villejuif, France
    Bull Cancer 97:149-59. 2010
    ..A recent analogue of thalidomide, probably more efficient, lenalidomide is also in development...
  76. pmc Bilateral germ-cell tumours: 22-year experience at the Institut Gustave Roussy
    Ch Theodore
    Department of Medicine, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94800 Villejuif, France
    Br J Cancer 90:55-9. 2004
    ..Therapeutic indications for synchronous BGCT, including conservative treatment, need to be better defined...
  77. ncbi request reprint [Prostate cancer: future strategies for chemotherapy management]
    K Fizazi
    Institut Gustave Roussy, 14, avenue Paul Vaillant Couturier, 94800 Villejuif, France
    Ann Urol (Paris) 41:S77-9. 2007
    ..The docetaxel plus estramustine association is likely more active than docetaxel alone. Docetaxel is currently tested in early stages: first results of phase III trials are expected by 2009-2010...
  78. ncbi request reprint A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors
    C Theodore
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 19:1465-9. 2008
    ..The aim of this study is to determine feasibility and efficacy of the combination regimen oxaliplatin and paclitaxel in patients with cisplatin (CDDP)-refractory germ-cell tumors (GCT)...
  79. ncbi request reprint Cisplatin-based chemotherapy regimen (DECAV) for uterine sarcomas
    P Pautier
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
    Int J Gynecol Cancer 12:749-54. 2002
    ..Median overall survival was 14 month overall, 45 months for Group 1 and 13 months for Group 2. We conclude that the DECAV regimen is clearly active in uterine sarcomas but is too toxic to be recommended routinely...
  80. ncbi request reprint A phase II monocentric study of oxaliplatin in combination with gemcitabine (GEMOX) in patients with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract
    C Theodore
    Institut Gustave Roussy, Villejuif, France
    Ann Oncol 17:990-4. 2006
    ..The aim of the study was to evaluate the activity and the safety of the gemcitabine-oxaliplatin (GEMOX) combination as first-line treatment in advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract...
  81. pmc Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?
    C Massard
    Department of Medicine, Institut Gustave Roussy, 39 rue Camille Desmoulins, Villejuif 94805, France
    Br J Cancer 97:857-61. 2007
    ..This finding may prompt clinical trials investigating EGFR inhibitors in this setting. In contrast, c-Kit expression and Her-2/neu overexpression occur infrequently in CUP. EGFR expression was correlated to tumour chemosensitivity...
  82. pmc Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer
    Nader Al Nakouzi
    Prostate Cancer Group, INSERM U981, Gustave Roussy, Villejuif, F 94805, France
    Oncotarget 5:667-78. 2014
    ....
  83. ncbi request reprint STEAP, a prostate tumor antigen, is a target of human CD8+ T cells
    Pedro M S Alves
    INSERM 487, Institut Gustave Roussy, 94805, Villejuif, France
    Cancer Immunol Immunother 55:1515-23. 2006
    ..These results show that STEAP can be a target of anti-tumor CD8(+) T cells and that STEAP peptides can be used for a broad-spectrum-tumor immunotherapy...
  84. ncbi request reprint Familial primary mediastinal nonseminomatous germ-cell tumors
    Adina Marti
    Institut Gustave Roussy, Villejuif, France
    Urol Oncol 22:421-4. 2004
    ..We discuss the relationship between these diseases of the mediastinum and the thymic microenvironment. Additionally, we suggest that a genetic predisposition for germ-cell tumors (GCT) may be involved since the parents were relatives...
  85. doi request reprint Carcinomas of an unknown primary origin--diagnosis and treatment
    Christophe Massard
    Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, 39 rue Camille Desmoulins, F 94800 Villejuif, France christophe massard igr fr
    Nat Rev Clin Oncol 8:701-10. 2011
    ..In this Review, we describe the clinical evaluation of patients with CUP, and discuss treatment strategies and outcomes of patients with various CUP subsets...
  86. ncbi request reprint Single-agent estramustine phosphate (EMP) is active in advanced breast cancer after failure with anthracyclines and taxanes
    L Zelek
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 12:1265-8. 2001
    ..The aim of the study was to assess its tolerance and efficacy in advanced breast cancer after failure with usual regimens...
  87. doi request reprint Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features
    Y Loriot
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 20:703-8. 2009
    ..The purpose of this study was to prospectively assess the anticancer activity and tolerance of the carboplatin-etoposide combination in this setting while evaluating neuroendocrine (NE) features...
  88. ncbi request reprint Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapy
    R De Crevoisier
    Department of Radiation, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 21:808-14. 2010
    ..The aim was to identify predictors of outcome in patients with localized prostate cancer treated with external beam radiotherapy (EBRT), with or without androgen deprivation therapy (ADT)...
  89. ncbi request reprint Bladder-conserving surgery and interstitial brachytherapy for lymph node negative transitional cell carcinoma of the urinary bladder: results of a 28-year single institution experience
    Renaud de Crevoisier
    Department of Radiation Oncology, Institut Gustave Roussy, 94805 Villejuif, France
    Radiother Oncol 72:147-57. 2004
    ..We retrospectively analyzed results for lymph node negative transitional cell carcinoma of the bladder treated with brachytherapy...
  90. ncbi request reprint Patient preference for either the EORTC QLQ-C30 or the FACIT Quality Of Life (QOL) measures: a study performed in patients suffering from carcinoma of an unknown primary site (CUP)
    C Rodary
    Department of Public Health, Institut Gustave Roussy, 39 rue Camille Desmoulin, 94805 Villejuif, France
    Eur J Cancer 40:521-8. 2004
    ..As no significant preference was observed for one of the questionnaires, the QLQ-C30 was chosen on the basis of its significantly better acceptability criteria...
  91. ncbi request reprint Poor prognosis nonseminomatous germ-cell tumours (NSGCTs): should chemotherapy doses be reduced at first cycle to prevent acute respiratory distress syndrome in patients with multiple lung metastases?
    C Massard
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 21:1585-8. 2010
    ..The management of these patients was modified at Institut Gustave Roussy in 1997 to try to avoid this complication...
  92. ncbi request reprint Acute respiratory distress syndrome after chemotherapy for lung metastases from non-seminomatous germ-cell tumors
    C Kirch
    Service de Reanimation Polyvalente, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Support Care Cancer 11:575-80. 2003
    ....
  93. doi request reprint Stemness markers characterize IGR-CaP1, a new cell line derived from primary epithelial prostate cancer
    Anne Chauchereau
    Prostate Cancer Group, INSERM U981, Institut Gustave Roussy, Villejuif F 94805, France
    Exp Cell Res 317:262-75. 2011
    ....
  94. pmc Ca125 and neuron-specific enolase (NSE) as tumour markers for intra-abdominal desmoplastic small round-cell tumours
    K Fizazi
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
    Br J Cancer 75:76-8. 1997
    ..However, normalization is frequently associated with an improvement of symptoms or a moderate clinical response...
  95. ncbi request reprint Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway
    J Yang
    Department of Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 61:5652-9. 2001
    ..Moreover, it allows to screen for therapeutic agents blocking the osteoblast response to prostate cancer...
  96. ncbi request reprint Association between germ cell tumours, large numbers of naevi, atypical naevi and melanoma
    M F Avril
    Department of Dermatology, Institut Gustave Roussy, Villejuif, France
    Melanoma Res 11:117-22. 2001
    ..Patients harbouring multiple pigmented spots should be referred for a skin examination aimed at early detection of curable melanomas, and should be advised to protect themselves from sun exposure...
  97. ncbi request reprint Treatment of patients with specific subsets of carcinoma of an unknown primary site
    K Fizazi
    Institut Gustave Roussy, Villejuif, France
    Ann Oncol 17:x177-80. 2006
  98. doi request reprint European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II
    Susanne Krege
    Department of Urology, Krankenhaus Maria Hilf, Krefeld, Germany
    Eur Urol 53:497-513. 2008
    ..In November 2006, the group met a second time under the auspices of the Department of Urology of the Amsterdam Medical Center, The Netherlands...
  99. doi request reprint European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I
    Susanne Krege
    Department of Urology, Krankenhaus Maria Hilf, Krefeld, Germany
    Eur Urol 53:478-96. 2008
    ..In November 2006, the group met a second time under the auspices of the Department of Urology of the Amsterdam Medical Center, Amsterdam, The Netherlands...
  100. ncbi request reprint A 10-year clinical experience with intermittent hormonal therapy for prostate cancer
    Dominique Prapotnich
    Department of Urology, Institut Mutualiste Montsouris, Universite Pierre et Marie Curie, Paris VI, 42 Boulevard Jourdan, 75674 Paris cedex, France
    Eur Urol 43:233-39; discussion 239-40. 2003
    ..To evaluate, over a 10-year period, the feasibility, efficacy, duration of action and adverse effects of intermittent hormonal therapy (IHT) in patients with advanced prostate cancer or biochemical recurrence after radical treatment...
  101. ncbi request reprint [Standards, Options and Recommendations for the management of patient with carcinoma of unknown primary site]
    Roland Bugat
    FNCLCC, Standards, Options, Recommandations, 101, rue de Tolbiac, 75654 Paris Cedex 13, France
    Bull Cancer 89:869-75. 2002
    ..Objectives: To develop clinical practice guidelines for carcinoma of unknown primary site (CUPS) patients according to the definitions of the Standards, Options and Recommendations project...